Fig. 1From: Clinical outcomes of immune checkpoint inhibitors to treat non-small cell lung cancer patients harboring epidermal growth factor receptor mutationsA The progression-free survival of 85 non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations treated with immune checkpoint inhibitor (ICI) combinations. B The overall survival of 85 NSCLC patients with EGFR mutations treated with ICI combinationsBack to article page